Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive...
The post-Fed stock market selloff on Wednesday helped cool off an overheated market. A larger downturn will come eventually to recalibrate overheated stocks. Thankfully, the bulls need not worry because...
/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Despite DexCom's lagging performance relative to the Nasdaq Composite over the past year, Wall Street analysts maintain a strong bullish outlook on the stock's prospects.
Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it...
Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services....
The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500, Nasdaq Composite , and...
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.
/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
This medical device company is down but not out.
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.